Caribbean cuisine

Kessler Topaz Meltzer & Check, LLP: Securities Fraud Class Action Lawsuit Filed Against Cassava Sciences, Inc.

Retrieved on: 
Saturday, September 4, 2021
Legal, Professional Services, Agriculture, Surnames, Food and drink, Staple foods, Tubers, Caribbean cuisine, Cassava, Crops, Jamaican cuisine, Kessler, Class action

The law firm of Kessler Topaz Meltzer & Check, LLP announces that a securities fraud class action lawsuit has been filed in the United States District Court for the Western District of Texas against Cassava Sciences, Inc. (NASDAQ: SAVA) (Cassava) on behalf of those who purchased or acquired Cassava securities between September 14, 2020 and August 27, 2021, inclusive (the Class Period).

Key Points: 
  • The law firm of Kessler Topaz Meltzer & Check, LLP announces that a securities fraud class action lawsuit has been filed in the United States District Court for the Western District of Texas against Cassava Sciences, Inc. (NASDAQ: SAVA) (Cassava) on behalf of those who purchased or acquired Cassava securities between September 14, 2020 and August 27, 2021, inclusive (the Class Period).
  • For additional information or to learn how to participate in this litigation please contact Kessler Topaz Meltzer & Check, LLP: James Maro, Esq.
  • Kessler Topaz Meltzer & Check, LLP prosecutes class actions in state and federal courts throughout the country involving securities fraud, breaches of fiduciary duties and other violations of state and federal law.
  • The complaint in this action was not filed by Kessler Topaz Meltzer & Check, LLP.

Cassava Sciences Reports Second Quarter 2021 Financial Results

Retrieved on: 
Tuesday, August 3, 2021
Agriculture, Food and drink, Caribbean cuisine, Cassava, Jamaican cuisine, Manihoteae, Tropical agriculture, Tubers

AUSTIN, Texas, Aug. 03, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimers disease, today announced financial results for the second quarter ended June 30, 2021.

Key Points: 
  • AUSTIN, Texas, Aug. 03, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimers disease, today announced financial results for the second quarter ended June 30, 2021.
  • Net cash use for operations for full-year 2021 is expected to be approximately $20 to $25 million, consistent with previous financial guidance.
  • Remi Barbier, President & CEO, and Eric Schoen, Chief Financial Officer, will host a conference call to review financial results and to preview the Companys growth strategy.
  • Cassava Sciences is also developing an investigational diagnostic, called SavaDx, to detect Alzheimers disease with a simple blood test.

Cassava Sciences Announces Conference Call for Second Quarter Financial Results

Retrieved on: 
Tuesday, August 3, 2021
Agriculture, Food and drink, Caribbean cuisine, Cassava, Jamaican cuisine, Manihoteae, Tropical agriculture, Tubers

Remi Barbier, President & CEO, and Eric Schoen, Chief Financial Officer, will host a conference call to review financial results and to preview the Companys growth strategy.

Key Points: 
  • Remi Barbier, President & CEO, and Eric Schoen, Chief Financial Officer, will host a conference call to review financial results and to preview the Companys growth strategy.
  • The conference call is scheduled to begin at 9:00 am ET on Tuesday, August 3, 2021.
  • Cassava Sciences mission is to discover and develop innovations for chronic, neurodegenerative conditions.
  • Over the past 10 years, Cassava Sciences has combined state-of-the-art technology with new insights in neurobiology to develop novel solutions for Alzheimers disease.

Internationally Award-Winning RUM Co. of Fiji Wins Top Consumer and Bartender Awards

Retrieved on: 
Wednesday, July 7, 2021
Rums, Distilled drinks, Alcoholic drinks, Sugar, Caribbean cuisine, Diageo brands, Hoochery Distillery, Captain Morgan

NEW YORK, July 7, 2021 /PRNewswire-PRWeb/ -- Internationally award-winning RUM Co. of Fiji , the only rum distillery in the Fiji Islands, is proud to announce that it has been recognized at the 2021 SIP Awards and Bartender Spirits Awards with its premium rum ranges, Bati and Ratu.

Key Points: 
  • NEW YORK, July 7, 2021 /PRNewswire-PRWeb/ -- Internationally award-winning RUM Co. of Fiji , the only rum distillery in the Fiji Islands, is proud to announce that it has been recognized at the 2021 SIP Awards and Bartender Spirits Awards with its premium rum ranges, Bati and Ratu.
  • Maturation accelerates in Fiji's Southern Hemisphere climate, so that RUM Co. of Fiji can achieve complex flavor profiles at younger ages.
  • "These awards support our passion and vision to make Fiji known as the new home of rum," he said.
  • Bati 2-Year Spiced Rum also won an exclusive Platinum "Best of Class" Award, while - - Ratu 5-Year Dark Rum and Bati 2-Year White Rum both won Platinum Awards; and
    Ratu 5-Year Spiced Rum and Bati 2-Year Dark Rum both took home Gold Medals.

Cassava Sciences to Present at the Raymond James 2021 Human Health Innovation Conference

Retrieved on: 
Thursday, June 17, 2021
Agriculture, Biofuels, Caribbean cuisine, Cassava, Jamaican cuisine, Tropical agriculture, Tubers, Food and drink, Branches of biology

AUSTIN, Texas, June 17, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimers disease, today announced that it has been invited to present at the Raymond James 2021 Human Health Innovation Conference, a virtual event taking place on June 21-23, 2021.

Key Points: 
  • AUSTIN, Texas, June 17, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimers disease, today announced that it has been invited to present at the Raymond James 2021 Human Health Innovation Conference, a virtual event taking place on June 21-23, 2021.
  • Remi Barbier, President & CEO, and Eric Schoen, Chief Financial Officer, will present a corporate overview on Tuesday, June 22nd at 3:20pm Eastern time.
  • Cassava Sciences mission is to discover and develop innovations for chronic, neurodegenerative conditions.
  • Over the past 10 years, Cassava Sciences has combined state-of-the-art technology with new insights in neurobiology to develop novel solutions for Alzheimers disease.

Global Cassava Processing Market (2021 to 2026) - Industry Trends, Share, Size, Growth, Opportunity and Forecasts - ResearchAndMarkets.com

Retrieved on: 
Monday, May 24, 2021
Other Manufacturing, Manufacturing, Agriculture, Crops, Staple foods, Tubers, Caribbean cuisine, Cassava, Jamaican cuisine, Branches of biology, Food and drink

The "Cassava Processing Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cassava Processing Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.
  • According to the publisher's latest report the global cassava processing market reached a volume of 298.8 Million Tons in 2020.
  • Looking forward, the publisher expects the global cassava processing market to exhibit moderate growth during the next five years.
  • The report has also analysed the key global players operating in the cassava processing market.

Cassava Sciences Announces Full-year 2020 Financial Results and Business Highlights

Retrieved on: 
Tuesday, March 23, 2021
Staple foods, Tubers, Caribbean cuisine, Cassava, Jamaican cuisine, Tropical agriculture, Plants, Branches of biology, Cuisine

AUSTIN, Texas, March 23, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimers disease, today announced financial results for the year ended December 31, 2020 and provided business updates.

Key Points: 
  • AUSTIN, Texas, March 23, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimers disease, today announced financial results for the year ended December 31, 2020 and provided business updates.
  • Cassava Sciences remains on-track to initiate two pivotal Phase 3 studies in second half of 2021.
  • Full Year 2020 Financial Results: Net loss in full-year 2020 was $6.3 million, or $0.24 per share, compared to a net loss in 2019 of $4.6 million, or $0.27 per share.
  • Cassava Sciences is also developing an investigational diagnostic, called SavaDx, to detect Alzheimers disease with a simple blood test.

Cassava Sciences Announces Closing of $200 Million Registered Direct Offering

Retrieved on: 
Friday, February 12, 2021
Staple foods, Tubers, Caribbean cuisine, Cassava, Jamaican cuisine, Manihoteae, Registration statement, NET, Branches of biology, Plants, Agriculture

AUSTIN, Texas, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) (the Company or Cassava Sciences), a clinical-stage biotechnology company focused on Alzheimers disease, today announced the closing of its previously announced registered direct offering of 4,081,633 shares of its common stock, at a purchase price per share of$49.00, for gross proceeds of approximately$200.0 million.

Key Points: 
  • AUSTIN, Texas, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) (the Company or Cassava Sciences), a clinical-stage biotechnology company focused on Alzheimers disease, today announced the closing of its previously announced registered direct offering of 4,081,633 shares of its common stock, at a purchase price per share of$49.00, for gross proceeds of approximately$200.0 million.
  • The net proceeds of the offering are estimated to be approximately $189.7 million, after deducting placement agent fees and other estimated offering expenses.
  • Cassava Sciences intends to use the net proceeds from this offering for working capital and general corporate purposes, including development of simufilam, the Companys lead drug candidate for the treatment of Alzheimers disease.
  • The offering was made only by means of a prospectus supplement that forms a part of the registration statement.

Cassava Sciences Announces Significant Program Progress and Expected Key Milestones in 2021 for Its Clinical Program in Alzheimer’s Disease

Retrieved on: 
Monday, February 8, 2021
Food and drink, Articles, Health, Caribbean cuisine, Cassava, Jamaican cuisine, Manihoteae, Tubers, Dementia

AUSTIN, Texas, Feb. 08, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company developing product candidates for Alzheimers disease, today announced significant program progress and expected milestones for 2021.

Key Points: 
  • AUSTIN, Texas, Feb. 08, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company developing product candidates for Alzheimers disease, today announced significant program progress and expected milestones for 2021.
  • Expected progress and key milestones in 2021 across Cassava Sciences product portfolio are summarized below.
  • Cassava Sciences plans to initiate a Phase 3 program of simufilam in Alzheimers disease in the second half of 2021.
  • Cassava Sciences Phase 3 program for simufilam consists of two large, double-blind, randomized, placebo-controlled studies of simufilam in patients with mild-to-moderate Alzheimers disease dementia.

Cassava Sciences Reports Third Quarter 2020 Financial Results

Retrieved on: 
Monday, November 9, 2020
Caribbean cuisine, Cassava, Jamaican cuisine, Manihoteae, Tropical agriculture, Tubers, Cash and cash equivalents, Branches of biology, Plants, Food and drink

AUSTIN, Texas, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimers disease, today reported financial results for the third quarter ended September 30, 2020.

Key Points: 
  • AUSTIN, Texas, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimers disease, today reported financial results for the third quarter ended September 30, 2020.
  • The Companys cash and cash equivalents were $24.1 million as of September 30, 2020, with no debt.
  • At September 30, 2020, cash and cash equivalents were $24.1 million, compared to $23.1 million at December 31, 2019, with no debt.
  • Over the past 10 years, Cassava Sciences has combined state-of-the-art technology with new insights in neurobiology to develop novel solutions for Alzheimers disease.